Viking Therapeutics shares surged significantly during Friday’s trading session following a bullish research note from Canaccord Genuity Group. The biopharmaceutical company’s stock gained substantial momentum after the firm issued a buy recommendation, reinforcing investor confidence in Viking’s developmental pipeline.
The equity reached approximately $38.88, marking a substantial recovery from recent lows around $25. This upward movement extended gains from Thursday’s session, when the stock had already advanced 7.3% after Viking disclosed plans to present new clinical data at upcoming medical conferences.
Critical November Presentations Loom
Market attention now focuses on two major November events that could determine the stock’s trajectory. Between November 4-7, Viking will present exploratory analyses from its Phase 2 VENTURE trial of VK2735 at ObesityWeek® 2025. Shortly afterward, from November 7-10, the company will reveal the design of its ongoing Phase 3 VANQUISH-1 and VANQUISH-2 studies at the American Heart Association Scientific Sessions 2025.
These presentations represent significant milestones for Viking’s flagship compound, VK2735—a dual GLP-1 and GIP receptor agonist competing in the rapidly expanding obesity treatment market. The company is developing both injectable and oral formulations of this therapeutic candidate.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
Short Squeeze Potential Adds Volatility
Trading dynamics are further complicated by notably high short interest representing approximately 23% of available float. This substantial bearish positioning could amplify price movements if positive clinical developments trigger a short covering rally.
Viking reported its quarterly financial results on October 22, posting losses consistent with clinical-stage biotechnology companies. The company’s financial position reflects considerable research and development expenditures, particularly those associated with preparing for costly Phase 3 clinical trials.
The upcoming data presentations will likely determine whether Viking’s shares continue their recent ascent or face renewed pressure, with the market eagerly awaiting clinical updates that could validate the company’s obesity treatment approach.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from November 1 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 1.
Viking Therapeutics: Buy or sell? Read more here...
